Xenon Pharmaceuticals reported Phase 3 X‑Tole2 results showing azetukalner reduced focal onset seizure frequency by 53.2% at the 25 mg dose and 34.5% at 15 mg versus placebo. The company said the data exceeded expectations and plans an FDA submission in the third quarter. CEO Ian Mortimer characterized the outcome as superior to prior pivotal epilepsy trials. The oral KV7 potassium channel opener produced a large placebo‑adjusted effect size and a tolerability profile with dose‑dependent dizziness and discontinuations concentrated at the higher dose. Analysts highlighted the 15 mg dose as commercially attractive given efficacy and lower drop‑out rates. Xenon’s timeline points to a rapid regulatory push that could add a new oral mechanism to focal epilepsy treatment if the FDA accepts the filing. Data were presented by Xenon in company releases and investor materials; the result immediately moved investor sentiment and may accelerate prescribing and competitive positioning in epilepsy if regulators agree on a benefit–risk profile.